212 related articles for article (PubMed ID: 36090976)
1. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
2. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
[TBL] [Abstract][Full Text] [Related]
3. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
[TBL] [Abstract][Full Text] [Related]
5. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
[TBL] [Abstract][Full Text] [Related]
7. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma.
Gong Y; Mao J; Liu M; Gao J
J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771
[TBL] [Abstract][Full Text] [Related]
8. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
[TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
10. Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report.
Lye YL; Shan B; Jia CH; Liu J; Hou J; Du WL; Feng R; Liang P
Ann Dermatol; 2023 May; 35(Suppl 1):S100-S102. PubMed ID: 37853877
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.
Liu Y; Tang J; Yu LY; Jiang Q
Explore (NY); 2023; 19(5):730-735. PubMed ID: 36878772
[TBL] [Abstract][Full Text] [Related]
14. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report.
Zhang L; Mai W; Hao B; Jiang W; Geng Q
Medicine (Baltimore); 2020 May; 99(21):e19790. PubMed ID: 32481252
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review.
Zhang M; Wu R; Jia M; Sun S; Zhang L; Tang T
Medicine (Baltimore); 2023 Oct; 102(41):e35659. PubMed ID: 37832081
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.
Zhang L; Wu Z
Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442
[TBL] [Abstract][Full Text] [Related]
17. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
Ai Q; Chen W; Li Y; Li G
Front Immunol; 2022; 13():840916. PubMed ID: 35720298
[TBL] [Abstract][Full Text] [Related]
18. Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report.
Li W; Zhai C; Che J; Wang W; Liu B
J Cardiothorac Surg; 2022 Jan; 17(1):10. PubMed ID: 35034650
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
20. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma.
Li X; Li G; Chen D; Su L; Wang RP; Zhou Y
Front Oncol; 2023; 13():912168. PubMed ID: 37781182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
